CLOSED
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and solid oral drug products for intermediates for anti-retroviral (ARV), anti-diabetic, cardiovascular, anti-asthma, ophthalmology, oncology, and gastroenterology. It also develops and manufactures animal-origin-free recombinant proteins and cell-culture media supplements and research and development services, including drug substance development, drug product development, and biologics development. In. Track Laurus Labs Limited's live NSE:LAURUSLABS share price ₹1,811.40 (-0.20%), market cap ₹₹979B, P/E 89.9. MarketRipple's AI analysis covers the investment thesis, ripple-chain impact, and Healthcare sector outlook for LAURUSLABS — real-time NSE India stock intelligence.
Open
₹1,821.00
High
₹1,838.30
Low
₹1,789.10
Prev. Close
₹1,815.00
52W High
₹1,826.60
52W Low
₹810.05
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and solid oral drug products for intermediates for anti-retroviral (ARV), anti-diabetic, cardiovascular, anti-asthma, ophthalmology, oncology, and gastroenterology. It also develops and manufactures animal-origin-free recombinant proteins and cell-culture media supplements and research and development services, including drug substance development, drug product development, and biologics development. In
Key Takeaway
Laurus Labs Limited is rated hold with a P/E of 89.9x — understand the valuation context before sizing a position.
★ Recommended
Ask AI: Is Laurus Labs Limited fairly valued right now?
Because a P/E of 89.9x needs to be compared against sector peers and growth expectations to be meaningful.
Continue Research
View events affecting Laurus Labs Limited
Because the investment case must account for macro and company-specific developments — events reveal the 'why' behind price moves.
Trace sector ripple effects
Because Healthcare moves create upstream and downstream implications that affect the entire thesis.
Intelligence Path
Growth
Govt Exposure
Policy Dependence
Execution Quality
News Sensitivity
Debt Strength
2,026 Cr
Revenue
368 Cr
Net Profit
0%
ROE
0%
ROCE
20.16
EPS
| ₹ in Crore | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|
| Revenue | 6,014 | 5,002 | 5,508 | 6,721 | 7,186 |
| Net Profit | 790 | 161 | 358 | 889 | 1,062 |
| ROE (%) | — | — | — | 0.0% | 0.0% |
| EPS (₹) | — | — | — | 20.16 | 20.16 |
| Debt/Equity | — | — | — | 46.4 | 46.4 |